FDA warned Amman Pharmaceutical Industries after a 2023 inspection found sterile drug manufacturing and data integrity failures.
What happened
FDA inspected the Amman, Jordan contract manufacturer of sterile OTC and homeopathic drugs from August 7 to 15, 2023. Investigators found deficient sterile manufacturing facility and equipment design, inadequate environmental and personnel monitoring, poor sterile technique, and equipment not sterilized. FDA also found unreliable laboratory records, overwritten laboratory equipment data, and quality unit oversight failures.
What FDA found
The sterile manufacturing areas and equipment were poorly designed and required many manual interventions that threatened product sterility.
21 CFR 211.42(c)(10)Environmental and personnel monitoring were inadequate, and airflow was not studied under production conditions.
21 CFR 211.42(c)(10)The company lacked adequate procedures to prevent microbial contamination and shipped sterile products before performing process simulations (media fills).
21 CFR 211.113(b)Operators used poor sterile technique and cleanroom behavior during filling.
21 CFR 211.113(b)Equipment touching sterile product parts was not sterilized.
21 CFR 211.113(b)Laboratory records were incomplete or unreliable, including missing microbial results and overwritten laboratory equipment data.
21 CFR 211.194(a)
What FDA wants
FDA asks the company to provide comprehensive independent contamination risk assessments, detailed remediation and corrective action plans, an independent environmental monitoring assessment, a data integrity investigation, and a quality unit remediation plan. No response deadline is stated in the letter.
Who should pay attention
- U.S. companies that buy sterile OTC or homeopathic drugs from this contract manufacturer
- brands relying on sterile contract manufacturing
- quality teams overseeing sterile drug suppliers
This is a summary. Read the original letter on fda.gov.